# NCT04649359 (NCT04649359)

> MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04649359
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Multiple Myeloma
- Interventions: Elranatamab (PF-06863135)
- Enrollment: 187
- Primary outcome: Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria

## Commentary we found

- YouTube: 44
- X threads: 21
- Podcasts: 18

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04649359

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04649359", "email": "<work email>"}; the inbox owner confirms by the emailed link.